SCHEMBL1027176

SCHEMBL1027176

Oc1ccnc(-c2ccccc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 2/20 0.59
MEN1 O00255 1/20 0.47
NTSR1 P30989 1/20 0.47
KMT2A Q03164 1/20 0.47
COMT P21964 1/20 0.46
MAPT P10636 2/20 0.46
TP53 P04637 1/20 0.46
HSD17B1 P14061 3/20 0.45
HSD17B2 P37059 3/20 0.45
KAT6A Q92794 1/20 0.45
FYN P06241 1/20 0.45
NPC1 O15118 2/20 0.45
LMNA P02545 1/20 0.45
RAB9A P51151 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
KMO O15229 1/20 0.44
CNR1 P21554 1/20 0.44
MIF P14174 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30574378 1.00 ASIC3 (0.59) ASIC3MEN1NTSR1KMT2ACOMT
SCHEMBL7433478 0.83 PDGFRB (0.44) ASIC3MAPTHSD17B1HSD17B2FYN
SCHEMBL1071219 0.81 CCR1 (0.48) MEN1KMT2AHSD17B1HSD17B2NPC1
SCHEMBL12131270 0.80 HSD17B1 (0.56) ASIC3MEN1NTSR1KMT2AHSD17B1
SCHEMBL21692157 0.79 ASIC3 (0.65) ASIC3MAPTNPC1LMNARAB9A
SCHEMBL27157236 0.79 NPC1 (0.56) MEN1KMT2AMAPTHSD17B1HSD17B2
SCHEMBL21228520 0.79 MAPT (0.56) MEN1KMT2AMAPTHSD17B1HSD17B2
SCHEMBL21390627 0.79 HSD17B1 (0.60) ASIC3HSD17B1HSD17B2FYNKMO
SCHEMBL29282119 0.79 KMO (0.53) MAPTTP53HSD17B1HSD17B2FYN
SCHEMBL30913194 0.79 KMO (0.53) MAPTTP53HSD17B1HSD17B2FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-03-31 US disclosed
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2026-02-26 US disclosed
US-20250230166-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2025-07-17 US disclosed
CN-119212707-A Oxadiazole HDAC6 inhibitors and uses thereof 艾科尼佐治疗股份有限公司 2024-12-27 CN disclosed
CN-113816863-B Triarylamine compound, preparation method thereof and organic light-emitting device 长春海谱润斯科技股份有限公司 2024-05-07 CN disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
WO-2023196601-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
CN-101360745-B 8-azabicyclo[3.2.1]octane derivatives useful as monoamine reuptake inhibitors N.V. ORGANON (NL) 2011-12-14 CN disclosed
EP-1957493-B1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS ORGANON NV (NL) 2011-01-19 EP disclosed
US-7605170-B2 8-azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2009-10-20 US disclosed
US-20090198052-A1 METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-08-06 US disclosed
EP-2022782-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE PIPERIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2009-02-11 EP disclosed
CN-101360745-A 8-azabicyclo[3.2.1]octane derivatives useful as monoamine reuptake inhibitors ORGANON NV (NL) 2009-02-04 CN disclosed
EP-1957493-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. Organon (NL) 2008-08-20 EP disclosed
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives N.V. ORGANON (NL) 2007-08-09 US disclosed
WO-2007063071-A1 8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS N.V. ORGANON (NL) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322747-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 ASIC3 3048/4885MEN1 4425/4885NTSR1 4542/4885
US-20250230166-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC11 ASIC3 3048/4885MEN1 4425/4885NTSR1 4542/4885
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC9 ASIC3 3640/4885MEN1 4699/4885NTSR1 4632/4885
US-20260055090-A1 OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, CTTN ASIC3 4284/4885MEN1 3173/4885NTSR1 3352/4885
US-20090198052-A1 METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS SNCA, SYNJ1, KCNH2 ASIC3 1424/4885MEN1 329/4885NTSR1 2276/4885
US-20070185156-A1 8-Azabicyclo[3.2.1]octane derivatives SLC22A8, SLCO1B3, SLCO1B1 ASIC3 1851/4885MEN1 2164/4885NTSR1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.